- Previous Close
3,335.00 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 5,930.00 - Volume
0 - Avg. Volume
129,591 - Market Cap (intraday)
83.447B - Beta (5Y Monthly) 0.29
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phytosphingosine and vitamin K2. The company also develops drug candidates for wet and dry macular degeneration, inflammatory bowel disease, anticancer, oral mucositis, nonalcoholic steatohepatitis, diabetic macular edema, and dry eye indications. The company was formerly known as GenoFocus, Inc. HLB Genex, Inc. was founded in 2000 and is based in Daejeon, South Korea.
hlbgenex.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 187420.KQ
View MorePerformance Overview: 187420.KQ
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 187420.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 187420.KQ
View MoreValuation Measures
Market Cap
80.67B
Enterprise Value
41.43B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.22
Price/Book (mrq)
3.39
Enterprise Value/Revenue
1.17
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-53.14%
Return on Assets (ttm)
-0.94%
Return on Equity (ttm)
-62.19%
Revenue (ttm)
35.43B
Net Income Avi to Common (ttm)
-18.83B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
83.81B
Total Debt/Equity (mrq)
157.94%
Levered Free Cash Flow (ttm)
47.36B